Renal impairment in Multiple Myeloma (MM) represents one of the most important factors that influences patient survival. In fact, before the introduction of modern chemotherapy, less than 25% of patients with acute kidney injury (AKI) and MM who required dialysis recovered sufficient renal function to become independent from dialysis, with a median overall survival of less than 1 year. There are many other factors involved in determining patient survival. In this study we aimed to investigate the role of double filter-based extracorporeal treatment for removal of serum free light chains (sFLC) in acute myeloma kidney (AKI for MM) and to evaluate patient overall survival. All patients received Bortezomib-based chemotherapy and extracorporeal treatment for sFLC removal. For each session 2 dialyzers of the same kind were used. The dialytic dose was not related to the degree of renal function but to the removal of sFLC. The factors that have been found to be significantly associated with lower mortality were reduction of sFLC at day 12 and day 30, >50% reduction of sFLC at day 30, number of sessions and independence from dialysis. Among baseline characteristics, albumin level was statistically associated with the patients' outcome. Our analysis highlights the importance of the early treatment for removal of sFLC in AKI for MM. These results indicate that the early removal of sFLC can improve patient's outcome.

Early Light Chains Removal and Albumin Levels with a Double Filter-Based Extracorporeal Treatment for Acute Myeloma Kidney / Donati, Gabriele; Zappulo, Fulvia; Maietti, Elisa; Scrivo, Anna; Gasperoni, Lorenzo; Zamagni, Elena; Tacchetti, Paola; Pantani, Lucia; Baraldi, Olga; Comai, Giorgia; Cappuccilli, Maria; Cavo, Michele; La Manna, Gaetano. - In: TOXINS. - ISSN 2072-6651. - 14:6(2022), pp. 1-13. [10.3390/toxins14060391]

Early Light Chains Removal and Albumin Levels with a Double Filter-Based Extracorporeal Treatment for Acute Myeloma Kidney

Donati, Gabriele;
2022

Abstract

Renal impairment in Multiple Myeloma (MM) represents one of the most important factors that influences patient survival. In fact, before the introduction of modern chemotherapy, less than 25% of patients with acute kidney injury (AKI) and MM who required dialysis recovered sufficient renal function to become independent from dialysis, with a median overall survival of less than 1 year. There are many other factors involved in determining patient survival. In this study we aimed to investigate the role of double filter-based extracorporeal treatment for removal of serum free light chains (sFLC) in acute myeloma kidney (AKI for MM) and to evaluate patient overall survival. All patients received Bortezomib-based chemotherapy and extracorporeal treatment for sFLC removal. For each session 2 dialyzers of the same kind were used. The dialytic dose was not related to the degree of renal function but to the removal of sFLC. The factors that have been found to be significantly associated with lower mortality were reduction of sFLC at day 12 and day 30, >50% reduction of sFLC at day 30, number of sessions and independence from dialysis. Among baseline characteristics, albumin level was statistically associated with the patients' outcome. Our analysis highlights the importance of the early treatment for removal of sFLC in AKI for MM. These results indicate that the early removal of sFLC can improve patient's outcome.
2022
14
6
1
13
Early Light Chains Removal and Albumin Levels with a Double Filter-Based Extracorporeal Treatment for Acute Myeloma Kidney / Donati, Gabriele; Zappulo, Fulvia; Maietti, Elisa; Scrivo, Anna; Gasperoni, Lorenzo; Zamagni, Elena; Tacchetti, Paola; Pantani, Lucia; Baraldi, Olga; Comai, Giorgia; Cappuccilli, Maria; Cavo, Michele; La Manna, Gaetano. - In: TOXINS. - ISSN 2072-6651. - 14:6(2022), pp. 1-13. [10.3390/toxins14060391]
Donati, Gabriele; Zappulo, Fulvia; Maietti, Elisa; Scrivo, Anna; Gasperoni, Lorenzo; Zamagni, Elena; Tacchetti, Paola; Pantani, Lucia; Baraldi, Olga; Comai, Giorgia; Cappuccilli, Maria; Cavo, Michele; La Manna, Gaetano
File in questo prodotto:
File Dimensione Formato  
toxins-14-00391.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 1.55 MB
Formato Adobe PDF
1.55 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1285204
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact